Search
Tenax Therapeutics Inc
TENXAdd to Watchlist
15.460USD
+2.170+16.33%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
375.30MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+16.33%
5 Days
+15.03%
1 Month
+39.40%
6 Months
+39.91%
Year to Date
+26.83%
1 Year
+166.09%
Key Figures
14.660Open
15.490High
3.89MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
16.04%Turnover Ratio
13.290Prev. Close
14.002Low
40.49MTurnover
LossP/E Static
3.27P/B
0.00%Div Yield TTM
-49.23%ROA
18.38052wk High
2.76Volume Ratio
-17.60MNet Profit
24.28MShares
-1.4042EPS TTM
0.98Beta
-51.71%ROE
5.34052wk Low
11.20%Amplitude
--Gross Margin
375.30MMarket Cap
4.76Reward/Risk
4.17%Risk Rate
TradingKey Stock Score of Tenax Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Tenax Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 86 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 36.20.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Tenax Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Tenax Therapeutics Inc Highlights
StrengthsRisks
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -11.01, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 11.71M shares, increasing 31.18% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 718.86K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.30.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
36.200
Target Price
+172.39%
Upside Space
Tenax Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Tenax Therapeutics Inc Info
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Ticker SymbolTENX
CompanyTenax Therapeutics Inc
CEOGiordano (Christopher T)
Websitehttp://www.tenaxthera.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Tenax Therapeutics Inc (TENX)?
The current price of Tenax Therapeutics Inc (TENX) is 15.46.
What is the symbol of Tenax Therapeutics Inc?
The ticker symbol of Tenax Therapeutics Inc is TENX.
What is the 52-week high of Tenax Therapeutics Inc?
The 52-week high of Tenax Therapeutics Inc is 18.38.
What is the 52-week low of Tenax Therapeutics Inc?
The 52-week low of Tenax Therapeutics Inc is 5.34.
What is the market capitalization of Tenax Therapeutics Inc?
The market capitalization of Tenax Therapeutics Inc is 375.30M.
Is Tenax Therapeutics Inc (TENX) currently rated as Buy, Hold, or Sell?
According to analysts, Tenax Therapeutics Inc (TENX) has an overall rating of STRONG BUY, with a price target of 36.20.
What is the Earnings Per Share (EPS TTM) of Tenax Therapeutics Inc (TENX)?
The Earnings Per Share (EPS TTM) of Tenax Therapeutics Inc (TENX) is -1.34.